CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,053 enrolled
Drug / intervention
GBS Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02270944
NCT02270944Phase 2Completed

A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years

GlaxoSmithKline·interventional·Posted Oct 22, 2014·Updated Dec 5, 2019

In Brief

A Phase 2 clinical trial evaluating GBS Vaccine for Infections, Streptococcal and Streptococcal Infections. Completed, enrolled 1,053 participants across 9 sites in 3 countries.

Detailed Summary

The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring reconstitution prior to administration), and of the lyophilized formulation of GBS Trivalent Vaccine, administered in non-pregnant and pregnant women in the clinical development program to date.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Czechia, United States
CollaboratorsNovartis Vaccines

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 22, 2014
Enrollment StartNov 20, 2014
Primary CompletionApr 23, 2015
Study CompletionSep 22, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.7 years ago

Interventions

GBS Vaccinebiological

Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus

GBS Vaccinebiological

Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus